Literature DB >> 30737052

The French Levothyrox® crisis: We did the best we could but….

Stéphane Mouly1, Matthieu Roustit2, Haleh Bagheri3, Marie-Christine Perault-Pochat4, Mathieu Molimard5, Régis Bordet6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30737052     DOI： 10.1016/j.therap.2019.01.003

Source DB:  PubMed          Journal:  Therapie        ISSN： 0040-5957            Impact factor:   2.070


× No keyword cloud information.
  3 in total

1.  Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.

Authors:  Guillaume L Martin; Julien Jouganous; Romain Savidan; Axel Bellec; Clément Goehrs; Mehdi Benkebil; Ghada Miremont; Joëlle Micallef; Francesco Salvo; Antoine Pariente; Louis Létinier
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.228

2.  Authors' Reply to Krebs-Brown et al. Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"

Authors:  D Concordet; P Gandia; J L Montastruc; A Bousquet-Mélou; P Lees; A A Ferran; P L Toutain
Journal:  Clin Pharmacokinet       Date:  2020-02       Impact factor: 6.447

3.  Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?

Authors:  Didier Concordet; Peggy Gandia; Jean-Louis Montastruc; Alain Bousquet-Mélou; Peter Lees; Aude A Ferran; Pierre-Louis Toutain
Journal:  Clin Pharmacokinet       Date:  2020-01       Impact factor: 6.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.